Journal of Clinical Toxicology
Open Access

Correction of abnormalities in a suite of 900 genes using intranasal vasoactive intestinal polypeptide restores gray matter nuclear atrophy and clinical functioning in Chronic Inflammatory Response Syndrome

4^th Global Summit on Toxicology

August 24-26, 2015 Philadelphia, USA

Ritchie C Shoemaker and James Ryan

Posters-Accepted Abstracts: J Clin Toxicol

Abstract :

Chronic Inflammatory Response Syndromes (CIRS) are typified by involvement of pro- and anti-inflammatory pathways;
coagulation parameters; TGF beta-1; split products of complement activation; autoimmunity; and dysregulation of regulatory
neuropeptides, including MSH and VIP. These syndromes are acquired following exposure to biologically produced toxins made by
dinoflagellates, cyanobacteria, bacteria, fungi and bacteria among others. The illnesses are multi-symptom and multisystem with a
unique group of proteomic findings demonstrated repeatedly in peer reviewed literature. Recently we published CNS abnormalities in
NeuroQuant , a volumetric software program most commonly used in patients with traumatic brain injury. The Next Generation RDA
Seq testing provided transcriptomic data that added a marked increase to assessment of the overall genomic effect of inflammatory
responses seen in CIRS. We report here a group of patients with typical CIRS treated with intranasal VIP who showed (1) correction
of typical genomic abnormalities and (2) resolution of gray matter nuclear atrophy seen on NeuroQuant; (3) resolution of persistent
symptoms, including executive neurocognitive symptoms. To date these combined findings are not reported in published literature.